BW 34
Alternative Names: BW-34Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Argo Biopharma
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cardiovascular disorders
Most Recent Events
- 30 Jan 2025 BW 34 is available for licensing as of 30 Jan 2025. https://www.argobiopharma.com/partnering/index.html(Argo Biopharma pipeline, January 2025)
- 30 Jan 2025 Early research in Cardiovascular disorders in China (Parenteral), before January 2025 (Argo Biopharma pipeline, January 2025)